TTFactor is the market connection company for IFOM and IEO research. TTFactor's mission is the commercial exploitation of IFOM and IEO fully integrated cancer capabilities, represented by:
One of the largest Molecular Oncology research center in Europe, Campus IFOM-IEO;
An innovative Experimental Therapeutics Unit, dedicated to drug discovery activities working on small molecules up to their IND ready status, through a scientific team with a strong industrial trackrecord.
From 2010 TTFactor serves Centro Cardiologico Monzino (part of IEO's Group) as consultant for all intellectual property and business development activities.
We are committed to identifying, protecting and transferring any intellectual property generated through research or clinical practise which may benefit from industrial development to become a product available to patients and the public at large.
Download the Company Full Text PDF brochure
Dr Carlo Ciani (Chairman of TTF) presents the TT program (in italian)
Interview with Daniela Bellomo (Managing Director of TTF)
A unique effort to discover new treatments for cancer, the Experimental Therapeutic Unit-IFOM leverages the strong biology and clinical relevance of the whole Campus IFOM and IEO’s research in cancer with industry-competitive drug discovery experience.
Via Adamello, 16 20139 MilanoT: +39 02 94375140 F +39 02 94375991e-mail:
TTFactor S.r.l.Sede legale: Via Ripamonti 435 MilanoSede Operativa Via Adamello 16 MilanoP.IVA/C.F. 07063660968